New FDA Approval: Immunomedics

New FDA Approval: Immunomedics

Trodelvy
May, 2020

Immunomedics is proud to announce that the U.S. Food and Drug Administration (FDA) has approved Trodelvy™ (sacituzumab govitecan-hziy)for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC)who have received at least two prior therapies for metastatic disease.Trodelvyis the first ADC approved bytheFDAspecifically for relapsedor refractorymetastatic TNBCand is also the first FDA-approved anti-Trop-2 ADC.

To read the full announcement, please click this link.

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members